您的账号已在其他设备登录,您当前账号已强迫下线,
如非您本人操作,建议您在会员中心进行密码修改

确定

vW因子联合D-二聚体预测非瓣膜性心房颤动患者抗凝治疗后发生血栓风险的研究

von Willebrand factor and D-dimer to evaluate the thrombosis risk in patients with nonvalvular atrial fibrillation in anti-coagulant therapy

摘要:

目的:研究血管性血友病因子抗原(vWF:Ag)含量和D-二聚体预测接受抗凝治疗的非瓣膜性心房颤动(NVAF)患者血栓风险的性能。方法:收集2017年3月至2019年3月间就诊的NVAF患者256例,其中男152例,女104例,年龄(57.9±20.4)岁;根据随访期内终点事件情况,将患者分为无事件组227例,血栓事件组29例。选择同期健康体检者作为对照组共50名,其中男30名,女20名,年龄(45.0±5.3)岁。用血液凝固仪测定血浆vWF:Ag水平,采用荧光免疫分析仪测定血浆D-二聚体水平。任意两组间数据比对采用Mann-Whitney U检验,多组间数据比对采用Kruskal-Wallis H检验,用Logistic回归对分类资料做多元相关性分析获得优势比( OR);用受试者工作特征(ROC)曲线评价vWF:Ag和D-二聚体预测血栓事件的性能;用Kaplan-Meier曲线进行生存分析;用Cox比例风险回归模型获得风险比( HR)。 结果:对照组的vWF:Ag和D-二聚体为103%(86%~131%)和249(90~522)μg/L,患者组为234%(102%~623%)和744(100~3 352)μg/L;在患者组中,无事件组为225%(102%~623%)和650(100~3 281)μg/L,血栓事件组为333%(210%~494%)和1 325(487~3352)μg/L;患者组的vWF:Ag和D-二聚体高于与健康对照组( P均<0.001),无事件组高于健康对照组( P均<0.001),血栓事件组高于无事件组( P均<0.001)。NVAF患者血浆vWF:Ag和D-二聚体水平均高于与对照组( P均<0.001)。无事件组患者的血浆vWF:Ag和D-二聚体水平高于健康对照组,差异有统计学意义( P均<0.001);血栓事件组患者的血浆vWF:Ag和D-二聚体水平均高于无事件组,差异有统计学意义( P均<0.001)。ROC显示,vWF:Ag预测NVAF患者3个月内血栓事件的临界值为229%时,曲线下面积为0.839(95% CI:0.784~0.894);D-二聚体的临界值为588 μg/L时,曲线下面积为0.803(95% CI:0.745~0.861);vWF:Ag联合D-二聚体,曲线下面积为0.868(95% CI:0.826~0.909)。Logistic回归分析显示,NVAF患者血浆vWF:Ag水平与年龄( OR=10.240, 95%CI 2.773~37.820)、慢性心力衰竭( OR=34.779, 95%CI 8.010~151.019)、高血压( OR=0.068, 95%CI 0.023~0.198)和2型糖尿病( OR=6.618, 95%CI 2.469~17.734)有显著相关性( P<0.001),与血管疾病( OR=4.801, 95%CI 1.204~19.145)有显著相关性( P=0.026);血浆D-二聚体水平与慢性心力衰竭( OR=0.146, 95%CI 0.036~0.588)、服药依从性( OR=0.114, 95%CI 0.016~0.832)有显著相关性( P值分别为0.007和0.032)。生存分析显示,血浆vWF:Ag、D-二聚体或vWF:Ag联合D-二聚体评估时,血浆水平高于临界值的患者在3个月内的血栓事件累积概率显著增高(Log-rank χ2分别为11.394、17.895和32.825, P均<0.001)。Cox比例回归模型显示,vWF:Ag和D-二聚体均不能独立预测抗凝治疗期间的血栓事件( HR分别为0.866和0.834, P值分别为0.253和0.152),但两项指标联合应用可显著改善预测性能( HR=0.780, P=0.048)。 结论:NVAF患者血浆vWF:Ag和D-二聚体水平变化与多种临床病理因素相关,并与患者3个月内的血栓风险密切相关,联合应用可为临床预测病情提供有效依据。

更多
abstracts:

Objective:To investigate the performance of von willebrand factor antigen (vWF:Ag) and D-dimer in predicting thrombotic risk in nonvalvular atrial fibrillation (NVAF) patients with anticoagulant therapy.Methods:From March 2017 to March 2019, 256 patients were enrolled, including 152 males and 104 females, aged (57.9±20.4) years old; according to the end-point events during the follow-up period, the patient group was further divided into 227 cases in the no-event group and 29 cases in the thrombotic event group;50 cases in the control group, including 30 males and 20 females, aged (45.0±5.3) years old. vWF:Ag was detected by blood coagulation instrument and determination of D-dimer was done by fluor-euzyme linked immunoassay Analyzer. Mann-Whitney U test was used for data comparison between any two groups, Kruskal-Wallis H test was used for comparison among multiple groups and multivariate correlation analysis was done by Logistic regression to obtain odds ratio ( OR). The prediction performance with thrombotic events of vWF:Ag and D-dimer was evaluated by ROC curve, Kaplan-Meier curve was used to analyze the survival curve and the hazard ratio ( HR) was obtained by Cox proportional hazard regression model. Results:The levels of vWF:Ag and D-dimer in the control group were 103% (86%-131%) and 249 (90-522) μg/L, 234% (102%-623%) and 744 (100-3 352) μg/L in the patient group; in the patient group, of which 225% (102%-623%) and 650 (100-3 281) μg/L in non-event group, 333% (210%-494%) and 1 325 (487-3 352) μg/L in thrombus event group; compared the healthy control, the levels of vWF:Ag and D-dimer were increased in patients group ( P<0.001), of which non-event groups were higher than healthy controls ( P<0.001), and the thrombotic event group was higher than that of the non-event group ( P<0.001). Plasma vWF:Ag level and D-dimer level in NVAF patients were higher than those in the control group ( P<0.001). Plasma vWF:Ag level and D-dimer level in the non-event group were significantly higher than those in the healthy control group ( P<0.001). The plasma vWF:Ag and D-dimer levels of patients in the thrombotic event group were significantly higher than those in the non-event group patients ( P<0.001). The result of ROC showed that the critical value of vWF: Ag for predicting thrombosis within 3 months of NVAF patients was 229% and area under the curve (AUC) was 0.839 (95% CI:0.784-0.894); When the critical value of D-dimer was 588 ng/ml, AUC was 0.803 (95% CI:0.745-0.861).While vWF:Ag combined with D-dimer, AUC was 0.868 (95% CI:0.826-0.909). Logistic regression analysis showed that plasma vWF:Ag level in NVAF patients was significantly correlated with age ( OR=10.240, 95%CI 2.773-37.820), congestive heart failure ( OR=34.779, 95%CI 8.010-151.019), hypertension ( OR=0.068, 95%CI 0.023-0.198) and type 2 diabetes ( OR=6.618, 95%CI 2.469-17.734) ( P<0.001), as well as was significantly correlated with vascular disease ( OR=4.801, 95%CI 1.204-19.145) ( P=0.026). Plasma D-dimer level was significantly correlated with congestive heart failure ( OR=0.146, 95%CI 0.036-0.588) and medication compliance ( OR=0.114, 95%CI 0.016-0.832) ( P value was 0.007 and 0.032). Survival analysis showed that the cumulative probability of thrombosis within 3 months was significantly increased (Log-rank χ2 was 11.394, 17.895 and 32.825 respectively, P value<0.001) in the patients with plasma levels above the critical value of vWF:Ag, D-dimer or vWF:Ag combined with D-dimer. Cox proportional regression model showed that neither vWF:Ag nor D-dimer could independently predict thrombotic events during anticoagulant therapy( HR was 0.866 and 0.834, P-value was 0.253 and 0.152, respectively), but it could improve the prediction performance significantly( HR=0.780, P=0.048) for combined application of both vWF:Ag and D-dimer. Conclusion:The changes with plasma vWF:Ag and D-dimer levels in NVAF patients were associated with a variety of clinicopathological factors and closely related to the risk of thrombosis within 3 months. Combined application could provide the effective basis for clinical prediction of the condition.

More
作者: 张伯玮 [1] 张珠博 [1] 任静 [1] 李杨 [1] 门剑龙 [1]
期刊: 《中华检验医学杂志》2020年43卷10期 1014-1020页 ISTICPKUCSCDCA
栏目名称: 论著
DOI: 10.3760/cma.j.cn114452-20200408-00372
发布时间: 2020-11-16
  • 浏览:6
  • 下载:7

加载中!

相似文献

  • 中文期刊
  • 外文期刊
  • 学位论文
  • 会议论文

加载中!

加载中!

加载中!

加载中!